CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 529 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy New ESMO Local and Locoregional Prostate Cancer Living Guideline v1.0 MOST POPULAR Rucaparib Approved as Maintenance Treatment for Some Recurrent Ovarian Cancers May 4, 2018 Saving Time for Patients and Improving Well-Being Through Mindfulness and Fitness:... October 23, 2023 New on NCI’s Websites for December 2020 December 31, 2020 Can Having Solar Panels or Living Near a Solar Farm Increase... January 4, 2022 Load more HOT NEWS Virchow: The Largest Foundation Model for Computational Pathology To Date Sacituzumab Govitecan Does Not Demonstrate a Statistically Significant OS Improvement in... Grieving for Your Old Life After Cancer Data Collection Analysis Demonstrates Changes in Lung Cancer Management Throughout the...
